As this protein was detected in both ERα positive and negative models, we analyzed by immunoblotting two triple-negative breast cancer (TNBC) cell lines, MDA-MB-453 and MDA-MB-231, also lacking ERα-FL expression and therefore resistant to fulvestrant treatment (Supplementary Fig. 1a). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.